Who Paid My Doc
Jose Rodriguez Vega
Thoracic Surgery (Cardiothoracic Vascular Surgery) Bayamon, PR Medical Doctor
NPI 1316940570 CMS profile 571539
1845 Carr 2, Ste 204, Bayamon, PR 00959
General payments
$4,937
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Jose Rodriguez Vega of Bayamon, PR is reported in the CMS Open Payments database as having received $4,937 across 46 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 50th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $4,535 | 35 | |
| 2023 | General | $125 | 1 | |
| 2020 | General | $67 | 3 | |
| 2019 | General | $210 | 7 |
Beside peers
- Jose Rodriguez Vega
- Thoracic Surgery (Cardiothoracic Vascular Surgery) median
- Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
- National median
In program year 2025, general payments to Jose Rodriguez Vega were reported at $0. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.
Show as a table
| Year | Jose Rodriguez Vega | Thoracic Surgery (Cardiothoracic Vascular Surgery) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $210 | $886 | $178–$3,167 | $163 |
| 2020 | $67 | $341 | $108–$1,605 | $114 |
| 2021 | $0 | $453 | $125–$1,886 | $132 |
| 2022 | $0 | $695 | $180–$2,566 | $149 |
| 2023 | $125 | $745 | $205–$2,662 | $160 |
| 2024 | $4,535 | $799 | $214–$2,967 | $164 |
| 2025 | $0 | $791 | $208–$3,074 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
60
Drug cost
$533
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Warfarin Sodium | Generic | 60 | $533 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Records
46 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Thoracic Surgery (Cardiothoracic Vascular Surgery) in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Thoracic Surgery (Cardiothoracic Vascular Surgery)
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.